Also trades as: NEU.AX (ASX) · $vol 8M
NURPF OTC
Neuren Pharmaceuticals Limited
1W: +2.4%
1M: -12.1%
3M: +19.0%
YTD: +10.6%
1Y: +19.0%
3Y: +62.8%
5Y: +1313.9%
$14.28
+0.34 (+2.42%)
Weekly Expected Move ±6.0%
$13
$13
$14
$15
$16
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Income Trends
Revenue
$65M
-70.2% ▼
5Y CAGR: +146.0%
Gross Profit
$65M
-64.9% ▼
5Y CAGR: +146.4%
Operating Income
$22M
-84.9% ▼
Net Income
$30M
-78.6% ▼
EPS (Diluted)
$0.24
-78.0% ▼
EBITDA
$22M
-87.7% ▼
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $3M | $15M | $232M | $217M | $65M |
| YoY Growth | +345.9% | +355.2% | +1493.7% | -6.5% | -70.2% |
| Cost of Revenue | $8K | $10K | $27M | $33M | $23K |
| Gross Profit | $3M | $15M | $205M | $184M | $65M |
| Gross Margin | 99.7% | 99.9% | 88.5% | 84.8% | 100.0% |
| R&D Expenses | $10M | $13M | $27M | $33M | $36M |
| SG&A Expenses | $2M | $3M | $6M | $5M | $6M |
| Operating Expenses | $11M | $16M | $33M | $38M | $43M |
| Operating Income | -$18M | -$2M | $172M | $146M | $22M |
| Operating Margin | -555.2% | -11.0% | 74.4% | 67.4% | 34.1% |
| Interest Expense | $0 | $0 | $0 | $0 | $0 |
| Income Before Tax | -$8M | -$680K | $205M | $183M | $39M |
| Tax Expense | $0 | -$864K | $48M | $41M | $8M |
| Net Income | -$8M | $184K | $157M | $142M | $30M |
| Net Margin | -243.8% | 1.3% | 67.7% | 65.5% | 47.1% |
| EPS (Diluted) | $-0.07 | $0.00 | $1.20 | $1.09 | $0.24 |
| EBITDA | -$8M | -$722K | $199M | $179M | $22M |
| Shares Outstanding | 118M | 129M | 131M | 131M | 131M |